Trial Profile
A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2024
Price :
$35
*
At a glance
- Drugs CNM Au8 (Primary)
- Indications Demyelinating disorders; Multiple sclerosis; Optic nerve disorders
- Focus Proof of concept; Therapeutic Use
- Acronyms VISIONARY-MS
- Sponsors Clene Nanomedicine
- 02 Mar 2024 Results (n=55) assessing long-term safety, efficacy, tolerability, and pharmacokinetics of CNM-Au8 30 mg in patients with stable RMS presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024
- 29 Feb 2024 Full clinical results for CNM-Au8 from this VISIONARY-MS Trial long-term open label extension (LTE) in participants with stable relapsing multiple sclerosis (RMS) totaling nearly three years of follow-up, presented in Clene Nanomedicine Media Release.
- 29 Feb 2024 According to a Clene Nanomedicine Media Release, company presented full clinical results for CNM-Au8 from this VISIONARY-MS Trial long-term open label extension (LTE) in participants with stable relapsing multiple sclerosis (RMS) totaling nearly three years of follow-up at the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum in West Palm Beach, Florida.